Joseph W. Arico is a patent agent in the Patent Counseling and Prosecution practice of Dechert’s Intellectual Property group. Dr. Arico has varied patent prosecution and intellectual property diligence experience, including drafting of new patent applications in small molecule, nucleic acids, chemical process and manufacturing, drug formulation and delivery, and diagnostic areas; prosecution of U.S. and foreign patent applications; patentability and freedom-to-operate substructure searching; and transactional due diligence evaluations of pharmaceutical and medical device patent estates.
Before joining Dechert in 2015, Dr. Arico worked as a patent agent in the Boston office of an international law firm. Prior to Dr. Arico’s legal career, he was a Walther Cancer Institute Postdoctoral Associate at the University of Notre Dame in the laboratories of Prof. Richard E. Taylor, where his research included the total synthesis of Tolypothrix polyethers and analogues of neopeltolide and epothilone natural products.
Notably, he prepared a small library of epothilone analogues for testing in an Alzheimer’s animal model in collaboration with a large pharmaceutical company.
Dr. Arico earned his Ph.D. at Boston College with Prof. Larry W. McLaughlin, where he synthesized nucleoside analogues for antiviral testing and to advance understanding of DNA structure; prepared oligonucleotides and examined their physical properties to study hydration in the minor groove of DNA; and developed new protecting group and glycosylation methods to prepare purine nucleosides more efficiently and rapidly.
- University of Notre Dame, B.S., Chemistry, 2004, cum laude
- Boston College, Ph.D., Organic Chemistry, 2010
- Suffolk University Law School, J.D., (Intellectual Property Concentration), Expected May 2018
ADMISSIONS : United States Patent and Trademark Office
- American Bar Association
- American Intellectual Property Association
- Prosecuting a patent portfolio and providing patent strategy advice for a French pharmaceutical company whose drug product, a combination of three known small molecule drugs, is in Phase 3 clinical trials for a rare genetic disease.
- Diligence evaluation of a US pharmaceutical company’s patent estate covering a cystic fibrosis small molecule drug candidate in the company’s US$88 million IPO.
- Diligence evaluation of multiple patent estates covering small molecule drug candidates on behalf of a European pharmaceutical company in its US$275 million IPO.
Rate : $$$$